{
    "clinical_study": {
        "@rank": "68806", 
        "arm_group": {
            "arm_group_label": "aTIV", 
            "arm_group_type": "Experimental", 
            "description": "Adult subjects \u226565 years of age received one dose of  a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere"
        }, 
        "brief_summary": {
            "textblock": "The present study is designed to confirm the safety and immunogenicity of trivalent, surface\n      antigen, inactivated influenza vaccine including MF59C.1 adjuvant, formulation 2013/2014\n      Northern Hemisphere, in adults \u226565 years of age.\n\n      For the immunogenicity endpoints the antibody response to each influenza vaccine antigen,\n      will be measured by means of Single Radial Hemolysis (SRH) or Hemagglutination Inhibition\n      (HI) at approximately 21 days post immunization.\n\n      The vaccine composition will be based on the World Health Organization (WHO) recommended\n      influenza strains for 2013/2014 Northern Hemisphere.\n\n      The results of this study are intended to support the use of this vaccine in future\n      influenza seasons if the recommended vaccine composition remains the same, in compliance\n      with the requirements of the current European Union (EU) recommendations for clinical trials\n      related to yearly licensing of influenza vaccines."
        }, 
        "brief_title": "Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults \u226565 Years of Age", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Adult subjects \u226565 years of age received one dose of  a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere", 
                        "title": "aTIV"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "63"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "5.0", 
                                            "@value": "71.9"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "year"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "29"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "34"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "Immunogenicity was assessed in terms of percentages of adult subjects \u226565 years of age with SRH areas \u226525mm2 against each of the three vaccine strains, three weeks after receiving one dose of aTIV.\nThe related European Committee for Human Medicinal Products (CHMP)  criterion for the assessment of immunogenicity is met if the percentage of subjects achieving  post vaccination SRH areas \u2265 25mm2 is >60%.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Adult subjects \u226565 years of age received one dose of  a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere", 
                                "title": "aTIV"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "61"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "33", 
                                                        "@upper_limit": "59", 
                                                        "@value": "46"
                                                    }
                                                }, 
                                                "sub_title": "Day 1 (H1N1 strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "78", 
                                                        "@upper_limit": "95", 
                                                        "@value": "89"
                                                    }
                                                }, 
                                                "sub_title": "Day 22 (H1N1 strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "30", 
                                                        "@upper_limit": "56", 
                                                        "@value": "43"
                                                    }
                                                }, 
                                                "sub_title": "Day 1 (H3N2 strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "80", 
                                                        "@upper_limit": "96", 
                                                        "@value": "90"
                                                    }
                                                }, 
                                                "sub_title": "Day 22  (H3N2 strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "17", 
                                                        "@upper_limit": "41", 
                                                        "@value": "28"
                                                    }
                                                }, 
                                                "sub_title": "Day 1 (B strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "66", 
                                                        "@upper_limit": "88", 
                                                        "@value": "79"
                                                    }
                                                }, 
                                                "sub_title": "Day 22 (B strain)"
                                            }
                                        ]
                                    }, 
                                    "description": "Immunogenicity was assessed in terms of percentages of adult subjects \u226565 years of age with SRH areas \u226525mm2 against each of the three vaccine strains, three weeks after receiving one dose of aTIV.\nThe related European Committee for Human Medicinal Products (CHMP)  criterion for the assessment of immunogenicity is met if the percentage of subjects achieving  post vaccination SRH areas \u2265 25mm2 is >60%.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Percentages of Subjects With Single Radial Hemolysis (SRH) Areas \u226525mm2, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV", 
                                    "units": "Percentage of subjects"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the per-protocol population i.e all subjects who have received study vaccination and provided immunogenicity data both at baseline and after vaccination;  did not withdraw informed consent and did not have Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) confirmed influenza during the study.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (baseline) and Day 22", 
                        "title": "Percentages of Subjects With Single Radial Hemolysis (SRH) Areas \u226525mm2, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Immunogenicity was assessed in terms of percentages of adult subjects \u226565 years of age achieving  seroconversion or significant increase in SRH area against each of the three vaccine strains, three weeks after receiving one dose of aTIV.\nSeroconversion is defined as percentage of subjects with a pre-vaccination SRH area \u22644mm2 achieving a post-vaccination SRH area \u226525 mm2. Significant increase is defined as percentage of subjects with a pre-vaccination SRH area >4mm2 achieving at least 50% increase in post-vaccination SRH area.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if>30% of subjects achieve seroconversion or significant increase in post-vaccination SRH area.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Adult subjects \u226565 years of age received one dose of  a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere", 
                                "title": "aTIV"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "61"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "44", 
                                                        "@upper_limit": "70", 
                                                        "@value": "57"
                                                    }
                                                }, 
                                                "sub_title": "H1N1 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "47", 
                                                        "@upper_limit": "73", 
                                                        "@value": "61"
                                                    }
                                                }, 
                                                "sub_title": "H3N2 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "57", 
                                                        "@upper_limit": "81", 
                                                        "@value": "70"
                                                    }
                                                }, 
                                                "sub_title": "B strain"
                                            }
                                        ]
                                    }, 
                                    "description": "Immunogenicity was assessed in terms of percentages of adult subjects \u226565 years of age achieving  seroconversion or significant increase in SRH area against each of the three vaccine strains, three weeks after receiving one dose of aTIV.\nSeroconversion is defined as percentage of subjects with a pre-vaccination SRH area \u22644mm2 achieving a post-vaccination SRH area \u226525 mm2. Significant increase is defined as percentage of subjects with a pre-vaccination SRH area >4mm2 achieving at least 50% increase in post-vaccination SRH area.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if>30% of subjects achieve seroconversion or significant increase in post-vaccination SRH area.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Percentages of Subjects With Seroconversion or Significant Increase in SRH Area, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV", 
                                    "units": "Percentage of subjects"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the per-protocol population", 
                        "safety_issue": "No", 
                        "time_frame": "Day 22", 
                        "title": "Percentages of Subjects With Seroconversion or Significant Increase in SRH Area, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The antibody responses following one dose of  aTIV were evaluated in terms of geometric mean ratio GMRs of post vaccination GMAs to pre vaccination GMAs against each of the three vaccine strains, three weeks after receiving one dose of aTIV.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if the GMR day 22/day 1 is > 2.0.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Adult subjects \u226565 years of age received one dose of  a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere", 
                                "title": "aTIV"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "61"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "2.04", 
                                                        "@upper_limit": "3.39", 
                                                        "@value": "2.63"
                                                    }
                                                }, 
                                                "sub_title": "H1N1 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "1.91", 
                                                        "@upper_limit": "2.87", 
                                                        "@value": "2.34"
                                                    }
                                                }, 
                                                "sub_title": "H3N2 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "2.35", 
                                                        "@upper_limit": "3.57", 
                                                        "@value": "2.89"
                                                    }
                                                }, 
                                                "sub_title": "B strain"
                                            }
                                        ]
                                    }, 
                                    "description": "The antibody responses following one dose of  aTIV were evaluated in terms of geometric mean ratio GMRs of post vaccination GMAs to pre vaccination GMAs against each of the three vaccine strains, three weeks after receiving one dose of aTIV.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if the GMR day 22/day 1 is > 2.0.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Geometric Mean", 
                                    "title": "Geometric Mean Ratio (GMR) of Post Vaccination Versus Pre Vaccination Geometric Mean Areas (GMAs), Against Each of Three Vaccine Strains After Receiving One Dose of aTIV", 
                                    "units": "Ratio"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the per-protocol population", 
                        "safety_issue": "No", 
                        "time_frame": "Day 22/Day 1", 
                        "title": "Geometric Mean Ratio (GMR) of Post Vaccination Versus Pre Vaccination Geometric Mean Areas (GMAs), Against Each of Three Vaccine Strains After Receiving One Dose of aTIV", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Immunogenicity was assessed in terms of percentages of adult subjects \u226565 years of age with HI titers \u226540, against each of the three vaccine strains, three weeks after receiving one dose of aTIV.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if the of subjects achieving HI titers \u2265 40 is >60%.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Adult subjects \u226565 years of age received one dose of  a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere", 
                                "title": "aTIV"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "61"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "63", 
                                                        "@upper_limit": "86", 
                                                        "@value": "75"
                                                    }
                                                }, 
                                                "sub_title": "Day 1 (H1N1 strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "89", 
                                                        "@upper_limit": "100", 
                                                        "@value": "97"
                                                    }
                                                }, 
                                                "sub_title": "Day 22 (H1N1 strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "78", 
                                                        "@upper_limit": "95", 
                                                        "@value": "89"
                                                    }
                                                }, 
                                                "sub_title": "Day 1 (H3N2 strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "94", 
                                                        "@upper_limit": "100", 
                                                        "@value": "100"
                                                    }
                                                }, 
                                                "sub_title": "Day 22  (H3N2 strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "47", 
                                                        "@upper_limit": "73", 
                                                        "@value": "61"
                                                    }
                                                }, 
                                                "sub_title": "Day 1 (B strain)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "91", 
                                                        "@upper_limit": "100", 
                                                        "@value": "98"
                                                    }
                                                }, 
                                                "sub_title": "Day 22 (B strain)"
                                            }
                                        ]
                                    }, 
                                    "description": "Immunogenicity was assessed in terms of percentages of adult subjects \u226565 years of age with HI titers \u226540, against each of the three vaccine strains, three weeks after receiving one dose of aTIV.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if the of subjects achieving HI titers \u2265 40 is >60%.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Percentages of Subjects With Haemagglutinin Inhibition(HI) Titers \u226540, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV.", 
                                    "units": "Percentage of subjects"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the per-protocol population", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (baseline) and Day 22", 
                        "title": "Percentages of Subjects With Haemagglutinin Inhibition(HI) Titers \u226540, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV.", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Immunogenicity was assessed in terms of percentages of adult subjects \u226565 years of age achieving seroconversion or significant increase in HI antibody titers after receiving one dose of aTIV.\nSeroconversion is defined as percentage of subjects with a pre-vaccination HI titer <10 to a post-vaccination titer \u226540. Significant increase is defined as percentage of subjects with a pre-vaccination HI titer \u226510 to at least a 4-fold increase in post-vaccination HI antibody titers.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if >30% of subjects achieve seroconversion or significant increase in post-vaccination HI titers.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Adult subjects \u226565 years of age received one dose of  a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere", 
                                "title": "aTIV"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "61"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "27", 
                                                        "@upper_limit": "53", 
                                                        "@value": "39"
                                                    }
                                                }, 
                                                "sub_title": "H1N1 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "30", 
                                                        "@upper_limit": "56", 
                                                        "@value": "43"
                                                    }
                                                }, 
                                                "sub_title": "H3N2 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "26", 
                                                        "@upper_limit": "51", 
                                                        "@value": "38"
                                                    }
                                                }, 
                                                "sub_title": "B strain"
                                            }
                                        ]
                                    }, 
                                    "description": "Immunogenicity was assessed in terms of percentages of adult subjects \u226565 years of age achieving seroconversion or significant increase in HI antibody titers after receiving one dose of aTIV.\nSeroconversion is defined as percentage of subjects with a pre-vaccination HI titer <10 to a post-vaccination titer \u226540. Significant increase is defined as percentage of subjects with a pre-vaccination HI titer \u226510 to at least a 4-fold increase in post-vaccination HI antibody titers.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if >30% of subjects achieve seroconversion or significant increase in post-vaccination HI titers.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Percentages of Subjects With Seroconversion or Significant Increase in HI Antibody Titers, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV", 
                                    "units": "Percentage of subjects"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the per-protocol population", 
                        "safety_issue": "No", 
                        "time_frame": "Day 22", 
                        "title": "Percentages of Subjects With Seroconversion or Significant Increase in HI Antibody Titers, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The antibody responses following one dose of  aTIV were evaluated in terms of GMRs of post vaccination geometric mean HI titers against each of the three vaccine strains, three weeks after receiving one dose of aTIV.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if the GMR day 22/day 1 is > 2.0.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Adult subjects \u226565 years of age received one dose of  a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere", 
                                "title": "aTIV"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "61"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "2.59", 
                                                        "@upper_limit": "4.91", 
                                                        "@value": "3.57"
                                                    }
                                                }, 
                                                "sub_title": "H1N1 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "2.45", 
                                                        "@upper_limit": "4.49", 
                                                        "@value": "3.32"
                                                    }
                                                }, 
                                                "sub_title": "H3N2 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "2.22", 
                                                        "@upper_limit": "3.26", 
                                                        "@value": "2.69"
                                                    }
                                                }, 
                                                "sub_title": "B strain"
                                            }
                                        ]
                                    }, 
                                    "description": "The antibody responses following one dose of  aTIV were evaluated in terms of GMRs of post vaccination geometric mean HI titers against each of the three vaccine strains, three weeks after receiving one dose of aTIV.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if the GMR day 22/day 1 is > 2.0.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Geometric Mean", 
                                    "title": "Geometric Mean Ratio (GMR) of Post Vaccination Versus Pre Vaccination HI Titers, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV", 
                                    "units": "Ratio"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the per-protocol population", 
                        "safety_issue": "No", 
                        "time_frame": "Day 22/Day 1", 
                        "title": "Geometric Mean Ratio (GMR) of Post Vaccination Versus Pre Vaccination HI Titers, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The number of adult subjects \u226565 years of age reporting solicited local and systemic adverse events and other solicited adverse events after receiving one dose of aTIV are reported.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Adult subjects \u226565 years of age received one dose of  a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere", 
                                "title": "aTIV"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "63"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "26"
                                                    }
                                                }, 
                                                "sub_title": "Any Local"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "Injection site induration"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "3"
                                                    }
                                                }, 
                                                "sub_title": "Injection site erythema"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "Injection site ecchymosis"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "21"
                                                    }
                                                }, 
                                                "sub_title": "Injection site pain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "15"
                                                    }
                                                }, 
                                                "sub_title": "Any systemic"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "Chills/shivering"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "Malaise"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "Myalgia"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "Arthralgia"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "11"
                                                    }
                                                }, 
                                                "sub_title": "Fatigue"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "5"
                                                    }
                                                }, 
                                                "sub_title": "Headache"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "Fever (\u2265 38\u00b0C)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "Temperature \u226540\u00b0C"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "Prophylactic use of analgesics/antipyretics (N=61)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "Therapeutic use of analgesics/antipyretics (N=61)"
                                            }
                                        ]
                                    }, 
                                    "description": "The number of adult subjects \u226565 years of age reporting solicited local and systemic adverse events and other solicited adverse events after receiving one dose of aTIV are reported.", 
                                    "param": "Number", 
                                    "title": "Number of Subjects Reporting Solicited Adverse Events After Receiving One Dose of aTIV", 
                                    "units": "Participants"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the safety set population i.e all subjects who have post-vaccination AE or reactogenicity records", 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 1 to Day 4 post vaccination", 
                        "title": "Number of Subjects Reporting Solicited Adverse Events After Receiving One Dose of aTIV", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The number of adult subjects \u226565 years of age subjects reporting any unsolicited adverse event (AEs) between Day 1 to 4 and serious adverse events (SAEs), medically attended AEs, AEs leading to withdrawal from the study between Day 1 to Day 22 after receiving one dose of aTIV are reported.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Adult subjects \u226565 years of age received one dose of  a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere", 
                                "title": "aTIV"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "63"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "12"
                                                    }
                                                }, 
                                                "sub_title": "Any AE"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "10"
                                                    }
                                                }, 
                                                "sub_title": "At least possibly related AEs"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "Serious AEs"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "At least possibly related SAEs"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "5"
                                                    }
                                                }, 
                                                "sub_title": "Medically attended AEs"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "AEs leading to withdrawal"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "Death"
                                            }
                                        ]
                                    }, 
                                    "description": "The number of adult subjects \u226565 years of age subjects reporting any unsolicited adverse event (AEs) between Day 1 to 4 and serious adverse events (SAEs), medically attended AEs, AEs leading to withdrawal from the study between Day 1 to Day 22 after receiving one dose of aTIV are reported.", 
                                    "param": "Number", 
                                    "title": "Number of Subjects Reporting Unsolicited Adverse Events After Receiving One Dose of aTIV", 
                                    "units": "Participants"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the unsolicited safety set population i.e all subjects who had  post-vaccination unsolicited AE records", 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 1 to Day 22 post-vaccination", 
                        "title": "Number of Subjects Reporting Unsolicited Adverse Events After Receiving One Dose of aTIV", 
                        "type": "Primary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Adult subjects \u226565 years of age received one dose of  a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere", 
                        "title": "aTIV"
                    }
                }, 
                "period_list": {
                    "period": {
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "63", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "63", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "0", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }
            }, 
            "point_of_contact": {
                "email": "RegistryContactVaccinesUS@novartis.com", 
                "name_or_title": "Posting Director", 
                "organization": "Novartis Vaccines and Diagnostics"
            }, 
            "reported_events": {
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "Adult subjects \u226565 years of age received one dose of  a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere", 
                        "title": "aTIV"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "32", 
                                            "@subjects_at_risk": "63"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "11", 
                                                "@subjects_at_risk": "63"
                                            }, 
                                            "sub_title": "Fatigue"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "63"
                                            }, 
                                            "sub_title": "Injection site erythema"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "21", 
                                                "@subjects_at_risk": "63"
                                            }, 
                                            "sub_title": "Injection site pain"
                                        }
                                    ]
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "5", 
                                            "@subjects_at_risk": "63"
                                        }, 
                                        "sub_title": "Headache"
                                    }
                                }, 
                                "title": "Nervous system disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "default_vocab": "MedDRA (Unspecified)", 
                    "frequency_threshold": "5"
                }, 
                "time_frame": "All solicited AEs and unsolicited AEs were collected from Day 1 to Day 4; all unsolicited SAEs, medically attended AEs, AEs leading to withdrawal from the study were collected from Day 1 to Day 22"
            }
        }, 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Human Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female volunteers aged 65 years or older, mentally competent, who gave\n             written informed consent prior to study entry;\n\n          -  Were able to comply with all the study requirements; and\n\n          -  Were in good health as determined by the outcome of medical history, physical\n             examination, and clinical judgment of the investigator.\n\n        Exclusion Criteria:\n\n          -  Had behavioral or cognitive impairment or psychiatric disease that, in the opinion of\n             the investigator, may have interfered with the subject's ability to participate in\n             the study;\n\n          -  Had a serious chronic or acute disease (in the judgment of the investigator)\n             including, but not limited to:\n\n               -  medically significant cancer (except for benign or localized skin cancer, cancer\n                  in remission for >= 10 years, or localized prostate cancer that has been\n                  clinically stable for > 2 years without treatment)\n\n               -  medically significant advanced congestive heart failure (ie, New York Heart\n                  Association [NYHA] class III and IV)\n\n               -  chronic obstructive pulmonary disease (ie, Global initiative for chronic\n                  Obstructive Lung Disease [GOLD] stage III and IV)\n\n               -  autoimmune disease (including rheumatoid arthritis and excepting Hashimoto's\n                  thyroiditis that has been clinically stable for >= 5 years)\n\n               -  diabetes mellitus type I\n\n               -  poorly controlled diabetes mellitus type II\n\n               -  advanced arteriosclerotic disease\n\n               -  history of underlying medical condition such as major congenital abnormalities\n                  requiring surgery, chronic treatment, or associated with developmental delay\n                  (eg, Down's syndrome)\n\n               -  acute or progressive hepatic disease\n\n               -  acute or progressive renal disease\n\n               -  severe neurological (especially Guillain-Barr\u00e9 syndrome) or psychiatric disorder\n\n               -  severe asthma\n\n          -  Had a history of any anaphylactic reaction and/or serious allergic reaction to any\n             component of the study vaccine.\n\n          -  Had a known or suspected (or have a high risk of developing) impairment/alteration of\n             immune function (excluding that normally associated with advanced age) resulting, for\n             example, from:\n\n               -  receipt of immunosuppressive therapy  (any parenteral or oral corticosteroid or\n                  cancer chemotherapy/radiotherapy) within the past 60 days and for the full\n                  length of the study,\n\n               -  receipt of immunostimulants within the past 6 months,\n\n               -  receipt of parenteral immunoglobulin preparation, blood products, and/or plasma\n                  derivates within the past 3 months and for the full length of the study, or\n\n               -  suspected or known human immunodeficiency virus (HIV) infection or HIV related\n                  disease.\n\n          -  Had known or suspected drug or alcohol abuse within the past 2 years;\n\n          -  Had bleeding diathesis or conditions associated with prolonged bleeding time that, in\n             the investigator's opinion, would have interfered with the safety of the subject;\n\n          -  Was not able to comprehend and to follow all required study procedures for the whole\n             period of the study;\n\n          -  Had a history or any illness that, in the opinion of the investigator, would have\n             posed additional risk to the subjects because of participation in the study;\n\n          -  Had the following within the past 6 months:\n\n               -  any laboratory confirmed seasonal or pandemic influenza disease,\n\n               -  received any seasonal or pandemic influenza vaccine.\n\n          -  Had received any other vaccine within 4 weeks prior to enrollment in this study or\n             who were planning to receive any vaccine during the study;\n\n          -  Had acute or chronic infections requiring antiviral therapy within the last 7 days;\n\n          -  Had experienced fever (ie, body temperature [preferably oral] >= 38.0\u00b0C) within the\n             last 3 days of intended study vaccination;\n\n          -  Had been participating in any clinical trial with another investigational product 4\n             weeks prior to first study visit or intended to participate in another clinical study\n             at any time during the conduct of this study;\n\n          -  Was part of study personnel or had close family members conducting this study;\n\n          -  Had a body mass index (BMI) >35 kg/m2 (BMI is calculated by dividing the subject's\n             weight in kilograms by the subject's height in meters multiplied by the subject's\n             height in meters)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "63", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 13, 2013", 
        "firstreceived_results_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01879540", 
            "org_study_id": "V70_44S", 
            "secondary_id": "2013-000607-16"
        }, 
        "intervention": {
            "arm_group_label": "aTIV", 
            "description": "Adjuvanted Trivalent Influenza Virus Vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)", 
            "intervention_name": "aTIV", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Influenza,", 
            "Elderly,", 
            "Immunology,", 
            "Safety"
        ], 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Antwerpen", 
                    "country": "Belgium", 
                    "state": "Wilrijk", 
                    "zip": "2610"
                }, 
                "name": "Antwerp University Centre for the Evaluation of Vaccination"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine Including MF59C.1 Adjuvant (Fluad\u00ae) in Healthy Adults \u226565 Years of Age", 
        "overall_official": {
            "affiliation": "Novartis Vaccines", 
            "last_name": "Novartis Vaccines and Diagnostics", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "European Union: European Medicines Agency", 
                "Belgium: Federal Agency for Medicinal Products and Health Products"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Immunogenicity was assessed in terms of percentages of adult subjects \u226565 years of age with SRH areas \u226525mm2 against each of the three vaccine strains, three weeks after receiving one dose of aTIV.\nThe related European Committee for Human Medicinal Products (CHMP)  criterion for the assessment of immunogenicity is met if the percentage of subjects achieving  post vaccination SRH areas \u2265 25mm2 is >60%.", 
                "measure": "Percentages of Subjects With Single Radial Hemolysis (SRH) Areas \u226525mm2, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (baseline) and Day 22"
            }, 
            {
                "description": "Immunogenicity was assessed in terms of percentages of adult subjects \u226565 years of age achieving  seroconversion or significant increase in SRH area against each of the three vaccine strains, three weeks after receiving one dose of aTIV.\nSeroconversion is defined as percentage of subjects with a pre-vaccination SRH area \u22644mm2 achieving a post-vaccination SRH area \u226525 mm2. Significant increase is defined as percentage of subjects with a pre-vaccination SRH area >4mm2 achieving at least 50% increase in post-vaccination SRH area.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if>30% of subjects achieve seroconversion or significant increase in post-vaccination SRH area.", 
                "measure": "Percentages of Subjects With Seroconversion or Significant Increase in SRH Area, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV", 
                "safety_issue": "No", 
                "time_frame": "Day 22"
            }, 
            {
                "description": "The antibody responses following one dose of  aTIV were evaluated in terms of geometric mean ratio GMRs of post vaccination GMAs to pre vaccination GMAs against each of the three vaccine strains, three weeks after receiving one dose of aTIV.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if the GMR day 22/day 1 is > 2.0.", 
                "measure": "Geometric Mean Ratio (GMR) of Post Vaccination Versus Pre Vaccination Geometric Mean Areas (GMAs), Against Each of Three Vaccine Strains After Receiving One Dose of aTIV", 
                "safety_issue": "No", 
                "time_frame": "Day 22/Day 1"
            }, 
            {
                "description": "Immunogenicity was assessed in terms of percentages of adult subjects \u226565 years of age with HI titers \u226540, against each of the three vaccine strains, three weeks after receiving one dose of aTIV.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if the of subjects achieving HI titers \u2265 40 is >60%.", 
                "measure": "Percentages of Subjects With Haemagglutinin Inhibition(HI) Titers \u226540, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV.", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (baseline) and Day 22"
            }, 
            {
                "description": "Immunogenicity was assessed in terms of percentages of adult subjects \u226565 years of age achieving seroconversion or significant increase in HI antibody titers after receiving one dose of aTIV.\nSeroconversion is defined as percentage of subjects with a pre-vaccination HI titer <10 to a post-vaccination titer \u226540. Significant increase is defined as percentage of subjects with a pre-vaccination HI titer \u226510 to at least a 4-fold increase in post-vaccination HI antibody titers.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if >30% of subjects achieve seroconversion or significant increase in post-vaccination HI titers.", 
                "measure": "Percentages of Subjects With Seroconversion or Significant Increase in HI Antibody Titers, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV", 
                "safety_issue": "No", 
                "time_frame": "Day 22"
            }, 
            {
                "description": "The antibody responses following one dose of  aTIV were evaluated in terms of GMRs of post vaccination geometric mean HI titers against each of the three vaccine strains, three weeks after receiving one dose of aTIV.\nThe related European (CHMP) criterion for the assessment of immunogenicity is met if the GMR day 22/day 1 is > 2.0.", 
                "measure": "Geometric Mean Ratio (GMR) of Post Vaccination Versus Pre Vaccination HI Titers, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV", 
                "safety_issue": "No", 
                "time_frame": "Day 22/Day 1"
            }, 
            {
                "description": "The number of adult subjects \u226565 years of age reporting solicited local and systemic adverse events and other solicited adverse events after receiving one dose of aTIV are reported.", 
                "measure": "Number of Subjects Reporting Solicited Adverse Events After Receiving One Dose of aTIV", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 4 post vaccination"
            }, 
            {
                "description": "The number of adult subjects \u226565 years of age subjects reporting any unsolicited adverse event (AEs) between Day 1 to 4 and serious adverse events (SAEs), medically attended AEs, AEs leading to withdrawal from the study between Day 1 to Day 22 after receiving one dose of aTIV are reported.", 
                "measure": "Number of Subjects Reporting Unsolicited Adverse Events After Receiving One Dose of aTIV", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 22 post-vaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01879540"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}